Clover Health Investments, Corp. — Form 8-K Summary
Business context and reporting period
This Form 8-K, dated April 20, 2023, reports a Nasdaq continued-listing deficiency for Clover Health’s Class A common stock, which trades under the symbol CLOV. It does not report quarterly or annual operating results.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-financial metrics. The filing text does not provide a clear current share price beyond stating that the closing bid price was below $1.00 for 30 consecutive business days.
Material change and listing status
- Nasdaq notified the Company that its common stock failed to satisfy the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
- The notice had no immediate effect on the listing; CLOV continued trading on the Nasdaq Global Select Market.
- The Company has until October 17, 2023, to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days, subject to possible Nasdaq discretion regarding the required period.
Outlook, contingencies, and risks
- If compliance is not regained, the Company may be eligible to transfer to the Nasdaq Capital Market for a potential additional 180-day compliance period, provided it meets applicable listing standards and gives required notice.
- If the Company fails to regain compliance during the applicable period, Nasdaq may issue a delisting determination. The Company could then appeal to a Nasdaq hearing panel.
- Management intends to monitor the closing bid price and consider available actions, potentially including seeking stockholder approval for a reverse stock split.
- There is no assurance that the Company will regain compliance, qualify for an additional compliance period, satisfy other Nasdaq requirements, or successfully appeal a delisting determination.
Key facts investors should verify
- Whether CLOV regained the $1.00 minimum bid price requirement by October 17, 2023.
- Whether Nasdaq granted or the Company pursued an additional compliance period through a transfer to the Nasdaq Capital Market.
- Whether stockholders approved or the Company implemented a reverse stock split.
- Any subsequent Nasdaq delisting notice, hearing, appeal, or change in trading market.
- The Company’s latest Form 10-K and subsequent filings for financial condition, liquidity, and related risk factors.